Phase 1 Trial of Subcutaneous [SC]; Outpatient Interleukin-2 for Patients With Advanced Mycosis Fungoides [Stage IIb, III, IV]
OBJECTIVES:
- Determine the maximum tolerated dose and toxicity of interleukin-2 in patients with
stage IIB-IV mycosis fungoides.
- Determine the response rate of patients treated with this regimen.
- Determine the immunologic response to this regimen in peripheral blood leukocytes and
serum of these patients.
OUTLINE: This is a dose escalation study.
Patients receive interleukin-2 (IL-2) subcutaneously on days 1-5 during weeks 1-3 and on
days 1-3 and 5 during week 4. Treatment repeats every 4 weeks for 4 courses.
Cohorts of 3-6 patients receive escalating doses of IL-2 until the maximum tolerated dose
(MTD) is determined. The MTD is defined as the dose at which 3 of 6 patients experience
dose-limiting toxicity. Six additional patients receive IL-2 at 1 dose level preceding the
MTD.
Patients are followed at least 3 times during year 1 and then annually thereafter.
PROJECTED ACCRUAL: A total of 16-30 patients will be accrued for this study.
Interventional
Primary Purpose: Treatment
John A. Thompson, MD
Study Chair
Seattle Cancer Care Alliance
United States: Federal Government
CDR0000064412
NCT00002687
February 1995
July 2003
Name | Location |
---|---|
University of Washington Medical Center | Seattle, Washington 98195-6043 |